Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Anke Van der Perren; Cindy Casteels; Koen Van Laere; Rik Gijsbers; Chris Van den Haute; Veerle Baekelandt

doi:10.3791/53670

Development of an Alpha-synuclein Based Rat Model for Parkinson’s Disease via Stereotactic ...

JoVE Journal
Medicine

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Medicine

Development of an Alpha-synuclein Based Rat Model for Parkinson’s Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Full Text

13,979 Views

08:33 min

February 28, 2016

DOI: 10.3791/53670-v

Anke Van der Perren¹, Cindy Casteels², Koen Van Laere², Rik Gijsbers^3,4, Chris Van den Haute^1,4, Veerle Baekelandt¹

¹Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences,KU Leuven, ²Division of Nuclear Medicine,Leuven University Hospital - KU Leuven, ³Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences,KU Leuven, ⁴Leuven Viral Vector Core,KU Leuven

Overview

This manuscript describes a method for developing a viral vector-based animal model for Parkinson's disease through stereotactic injection in the central nervous system. This technique allows for targeted gene expression in specific brain regions, facilitating pre-clinical drug testing and the study of neurodegenerative disorders.

Key Study Components

Area of Science

Neuroscience
Gene Therapy
Neurodegenerative Disorders

Background

Viral vector-mediated gene delivery is an effective method for gene expression in the brain.
This approach can create animal models for studying diseases like Parkinson's.
Specific targeting of brain regions enhances the relevance of the models.
Different vector systems can be tailored based on the research needs.

Purpose of Study

To develop a reliable animal model for Parkinson's disease.
To facilitate pre-clinical testing of potential therapies.
To explore the molecular mechanisms underlying Parkinson's disease.

Methods Used

Stereotactic injection of viral vectors into the substantia nigra.
Selection of vector systems based on gene size and expression duration.
Targeting specific animal strains and species for model development.
Assessment of gene expression levels in the brain.

Main Results

Successful gene delivery to targeted brain regions.
Establishment of a functional animal model for Parkinson's disease.
High levels of transgene expression observed.
Potential for further studies on neurodegenerative mechanisms.

Conclusions

The method provides a valuable tool for Parkinson's disease research.
Viral vector-mediated delivery can enhance understanding of neurodegeneration.
Future applications may include testing new therapeutic strategies.

Frequently Asked Questions

What is the main advantage of using viral vectors?

Viral vectors allow for specific targeting of brain regions and high levels of gene expression.

How does this method contribute to Parkinson's disease research?

It enables the development of animal models that can be used for pre-clinical drug testing and studying disease mechanisms.

What are the considerations when choosing a viral vector?

Factors include the size of the gene to be expressed, duration of expression, and safety issues.

Can this method be applied to other neurodegenerative disorders?

Yes, the technique can be adapted for various neurodegenerative diseases beyond Parkinson's.

What is stereotactic injection?

It is a precise method for delivering substances into specific brain areas using a three-dimensional coordinate system.

What types of animal models can be developed using this technique?

Models can be created in different animal strains and species, tailored to specific research needs.

This manuscript describes how viral vector-mediated local gene delivery provides an attractive way to express transgenes in the central nervous system. The protocol outlines all crucial steps to perform a viral vector injection in the substantia nigra of the rat to develop a viral vector-based animal model for Parkinson's disease.

The overall goal of this procedure is to develop a viral vector based animal model for Parkinson's Disease via Stereotactic Injection in the central nervous system. This method can be used to develop normal animal models which allow for pre-clinical drug testing and can be beneficial in studying the molecular mechanism of Parkinson's Disease as well as many other neurodegenerative disorders. The main advantage of this technique is that it can be used for specific targeting of brain regions.

High trenching brain expression can be achieved and that it can be used to create animal models in specific animal strains and species. The different final vector systems have been developed. The choice of the vector system depends on the size of the trenching you want to express, the duration of the gene expression, the sounds that you want to target, and bio-safety issues.

View the full transcript and gain access to thousands of scientific videos